One example of prior work is translational research from PALOMA-3, a phase III multicenter, double-blind randomized control trial of Palbociclib plus Fulvestrant vs placebo plus Fulvestrant in women with HR+/HER2− advanced breast cancer. Here, ERBB2 is linked to breast cancer.